Abstracts Archive - Page 521 of 1683 - ATC Abstracts

2020 American Transplant Congress
Effectiveness and Tolerability of Cidofovir for the Management of BK Viremia in Kidney Transplant Recipients
M. Thornberg¹, J. Hedvat¹, N. Lange¹, C. Brennan², D. Salerno¹, D. Tsapepas²
¹NewYork-Presbyterian Hospital, Department of Pharmacy, New York, NY, ²Columbia Irving University Medical Center, Department of Transplant Surgery, New York, NY
*Purpose: BK viremia (BKV) is a common complication after kidney transplantation (KT) that often leads to graft dysfunction and loss. Without consensus management guidelines and…
2020 American Transplant Congress
De Novo Malignancy after Liver Transplantation for Alcoholic Cirrhosis: Incidence and Outcomes
M. M. Pascale, E. Nure, G. Bianco, F. Frongillo, S. Agnes
Transplant Unit, Fondazione "Policlinico A. Gemelli" UCSC - Rome, Roma, Italy
*Purpose: De novo malignancy, frequent liver transplant (LT) complication, is one of the long-term major causes of mortality. Risk factors are related to immunosuppressive status,…
2020 American Transplant Congress
Everolimus for BKV Nephropathy in Kidney Transplant Recipients: A Prospective, Controlled Study
E. Bussalino¹, D. Bellino¹, L. Marsano¹, F. Massarino¹, R. Russo¹, I. Fontana², G. Zaza³, G. Stallone⁴, E. Paoletti¹
¹Nephrology, Dialysis, and Transplantation, Policlinico San Martino Genova, Genova, Italy, ²Transplantation Unit, Policlinico San Martino Genova, Genova, Italy, ³Renal Unit, Department of Medicine,, University Hospital of Verona, Verona, Italy, ⁴Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
*Purpose: Polyoma BK virus nephropathy (BKVN) of KTRs is associated with adverse outcome, since no specific therapy exists. EVR showed promising antiviral effects but systematic…
2020 American Transplant Congress
Reactivation of BK Polyomavirus after Kidney Transplantation: A Multi-Center Collaboration Examining the Impact of Adherence to a Screening Protocol on Clinical Outcomes
R. Rogers¹, F. Cheema², M. Chobanian³, Z. Ebcioglu², H. Gilligan⁴, R. Gohh¹, N. Goyal⁵, M. Pavlakis⁶, N. Rodig⁷, A. Rossi⁸, J. Singh², C. S. Tan⁶
¹Warren Alpert Medical School of Brown University, Providence, RI, ²Hartford Hospital, Hartford, CT, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Massachusetts General Hospital, Boston, MA, ⁵Tufts University School of Medicine, Boston, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Boston Children's Hospital, Boston, MA, ⁸Maine Medical Center, Portland, ME
*Purpose: Reactivation of BK polyomavirus (BK) after kidney transplantation (KT) is common and can lead to adverse clinical outcomes such as allograft nephropathy (BKAN). In…
2020 American Transplant Congress
Outcome of Hepatitis B Virus DNA-Positive Liver Transplantation in Hepatitis B Virus/Hepatitis D Virus Co-Infected Recipient Treated with High Dose Hepatitis B Immune Globulin: A Case Report
M. B. Hammami¹, M. Haris¹, L. Toman¹, N. Danis¹, B. Saberi², E. King³, J. Garonzik-Wang³, B. Philosophe³, A. M. Cameron³, A. Gurakar¹
¹Gastroenterology and Hepatology, Johns Hopkins, Baltimore, MD, ²Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Transplant Surgery, Johns Hopkins, Baltimore, MD
*Purpose: Introduction: While common in Asian countries, liver transplantation (LT) for patients with hepatitis B virus (HBV)/hepatitis D virus (HDV) co-infection is rare in the…
2020 American Transplant Congress
Brincidofovir for Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid Organ Transplant Recipients
J. Londeree¹, R. Garro¹, R. Romero², R. George¹, P. Winterberg¹, R. Liverman³, A. Serluco³, S. Shin¹, I. Yildirim⁴
¹Pediatric Nephrology, Emory, Atlanta, GA, ²Pediatric Hepatology and Gastroenterology, Emory, Atlanta, GA, ³Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA, ⁴Pediatric Infectious Disease, Emory, Atlanta, GA
*Purpose: Brincidofovir (BCV) is an investigational antiviral drug with potency against Human Adenovirus (HAdV). We describe four cases of disseminated HAdV infection treated with (BCV)…
2020 American Transplant Congress
Duration of Pre-Transplant Abstinence Does Not Predict Severe Relapses of Alcohol Abuse in High-Risk Alcoholic Liver Transplant Recipients
W. H. Kitchens
Emory Transplant Center, Atlanta, GA
*Purpose: The traditional requirement of >6 months pre-transplant sobriety for liver transplant recipients has been challenged by emerging literature, but risk factors for post-transplant recidivism…
2020 American Transplant Congress
Sequence Variations of the LMP1 Protein are Detected in Pediatric Transplant Recipients and May Increase the Risk of EBV Disease
B. Mbiribindi¹, M. Arvedson¹, J. Pena¹, O. Hatton², C. Esquivel¹, O. Martinez¹, S. Krams¹
¹Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ²Molecular Biology, Colorado College, Colorado Springs, CO
*Purpose: Epstein-Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a…
2020 American Transplant Congress
Association between Alcoholic Liver Disease and Alcohol Tax
S. Melo¹, A. Ermekbaeva², J. Buggs³, E. Rogers³, A. Kumar⁴, N. Kemmer⁵
¹School of Medicine, Indiana University, Indianapolis, IN, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴Morsani College of Medicine, University of South Florida, Tampa, FL, ⁵Transplant Hepatology, Tampa General Hospital, Tampa, FL
*Purpose: The incidence of Alcoholic Liver Disease (ALD) has increased, causing ALD to become a primary indication for liver transplantation in the United States. We…
2020 American Transplant Congress
Potential Cost-Savings Associated with ANG-3777 for the Treatment of Delayed Graft Function in Kidney Transplantation
M. Cooper¹, T. Mayne², T. Kauf³, M. Gargano³, K. Freemyer³
¹Medstar Georgetown Transplant Institute, Washington, DC, ²Angion Biomedica Corp, San Francisco, CA, ³Genesis Research, Hoboken, NJ
*Purpose: We created a medical cost offset model based upon the results of a Phase 2, double-blind, randomized controlled trial of ANG-3777, a hepatocyte growth…